Latest projects

3rd Health Programme (2014-2020)
YOUNG50 #Stay Healthy - Cardiovascular Risk Prevention [YOUNG50]
Cardiovascular diseases (CVDs) are a leading cause of mortality in the European Union causing over 1.8 million deaths per year (EHN Cardiovascular Disease Statistics) as well as a great loss in poten...
Cardiovascular diseases (CVDs) are a leading cause of mortality in the European Union causing over 1.8 million deaths per year (EHN Cardiovascular Disease Statistics) as well as a great loss in potential life years.
YOUNG50 project will transfer the Italian best practice CARDIO 50 project in Lithuania, Romania, Luxembourg among 50 years olds.
The objectives of CARDIO 50 were to estimate cardiovascular risk among the 50 years old population, identify persons with inadequate life styles, new cases of hypertension, hyperglycemia and hyper cholesterolemia, activate an integrated model of assistance to help modify or reduce risk factors among healthy subjects, promote interventions to change unhealthy lifestyles and increase knowledge and perceptions of CVD risks among the general population.
The implementation of YOUNG 50 will be divided into 3 phases. Phase1 will assess the feasibility of the implementation in each MSs though a situation analysis and adaptation of the existing materials and IT tools to the local context with support from Spain. In Phase2 the YOUNG50 programme will be piloted in selected regions or cities, with the involvement of health professionals and prevention programs. Phase3 will evaluate the impact of the action and explore its institutionalization.
With early detection, treatment of risk factors and follow up it is envisaged to have results regarding people who receive counseling and improve their lifestyles or medical parameters. Participating countries can beneficiate from the dissemination of the program, since the needs assessment in these countries indicated a need for such a project. Countries can take advantage of transfer and scaling-up of innovative prevention models, including the use of information and communication technology.
Outcomes expected are synergy among prevention programs, inclusion of CVD prevention in Regional or National Health Plan, development of recommendations and Policy Guidelines.
Start date: 01/05/2019 - End date: 30/04/2022

Call: Call for Proposals for Projects 2018 - Implementation of best practices to promote health and prevent non-communicable diseases and to reduce health inequalities
Topic: 1.1 Cost-effective promotion and prevention measures in line, in particular, with the Union strategies on alcohol and nutrition, and including actions to support the exchange of evi...
Topic: 1.1 Cost-effective promotion and prevention measures in line, in particular, with the Union strategies on alcohol and nutrition, and including actions to support the exchange of evidence-based and good practices for addressing risk factors such as tobacco use and passive smoking, harmful use of alcohol, unhealthy dietary habits and physical inactivity, taking into account the public health aspects of underlying factors, such as those of a social and environmental nature, with a focus on Union added value.
3rd Health Programme (2014-2020)
Strengthened International HeAlth Regulations and Preparedness in the EU - Joint Action [SHARP JA]
The SHARP Joint Action will strengthen implementation of Decision 1082/2013/EU, supporting the EU level preparedness and responses to health threats and the implementation of the International Health ...
The SHARP Joint Action will strengthen implementation of Decision 1082/2013/EU, supporting the EU level preparedness and responses to health threats and the implementation of the International Health Regulations (2005). The Joint Action implements actions mentioned in Annex 1 of the Annual Work plan 2018 of the EU Health Programme 2014-2020.
Through the Joint Action, the member and partner states and the Unions common ability to prevent, detect and respond to biological outbreaks, chemical contamination and environmental and unknown threats to human health will be strengthened. Special efforts will be employed to fill gaps that have been or will be identified in priority countries (countries that have biggest gaps in the capacity required for full IHR capability). The Joint action consists of 10 Work Packages, covering core public health capacities according to the IHR (2005). In addition to a coordination function, these will cover areas such as Communication, Evaluation, Sustainability, IHR core capacity, Preparedness, Laboratories, Training and exercises, Chemical threats and Clinical management.
SHARP will also collaborate with several other Joint Actions, specifically the “Healthy Gateways” that addresses Points of Entry, the Joint Action on Vaccination (EU-JAV) and the Joint Action on Antimicrobial Resistance (EU-JAMRAI).
The partnership of the joint action consists of 26 Associated Partners and 33 Affiliated Entities, which all will receive Commission co-funding. In addition there are 9 Collaborating Partners that will self-fund all activities that they participate in. Totally 30 countries (24 EU members, 3 EEA/EFTA members and 3 European neighborhood countries) participate in the Joint Action. The SHARP JA will liaise with and collaborate with the ECDC, the WHO EURO regional office and the WHO Health Emergency and IHR unit in Lyon, and IANPHI in relevant activities. Special emphasis will be made to avoid duplication of work for the member states.

Start date: 01/04/2019 - End date: 31/03/2022

Call: Joint Actions 2018
Topic: 2.2 Support capacity-building against health threats in Member States, including, where appropriate, cooperation with neighbouring countries: develop preparedness and response plann...
Topic: 2.2 Support capacity-building against health threats in Member States, including, where appropriate, cooperation with neighbouring countries: develop preparedness and response planning taking into account, and coordinating with, global initiatives, components of generic and specific preparedness planning, public health response coordination, non-binding approaches on vaccination; address the increasing health threats resulting from global population movements; develop guidelines on protective measures in an emergency situation, guidelines on information and guides to good practice; contribute to the framework for a voluntary mechanism, including the introduction of optimal vaccination coverage to effectively combat the resurgence in infectious diseases and for joint procurement of medical countermeasures; develop coherent communication strategies.
3rd Health Programme (2014-2020)
EpiCARE - a European Reference Network for rare and complex epilepsies [ERN EPICARE]
ERN EpiCARE is a network of 28 centres with expertise in the rare and complex epilepsies across 13 countries, developed to enhance diagnosis and ultimate management of these diseases. Complex epilepsi...
ERN EpiCARE is a network of 28 centres with expertise in the rare and complex epilepsies across 13 countries, developed to enhance diagnosis and ultimate management of these diseases. Complex epilepsies are those requiring multidisciplinary management through a care pathway or for comorbidity, with or without known aetiology, for example the surgically treatable epilepsies requiring a high level of multidisciplinary expertise and diagnostic resource (including video-EEG analysis, functional and/or structural neuroimaging). Delivery of such expertise can be enhanced through the use of e-tools, minimising the need for patients to travel. EpiCARE activities over the third, fourth and fifth years will be targeted at consolidating and further developing the EpiCARE network. EpiCARE aims at improving accessibility of detailed diagnostics to individuals of all ages with rare and complex epilepsies across Europe, including clinical evaluation and investigation. A care pathway for patients’ referral will be established throughout Europe, and further linkage with national health care networks will be coordinated. Online tools to aid the diagnosis of patients will be established. The development of treatment protocols and the monitoring of standardised outcomes of rare and complex epilepsies will be continued. Awareness and accessibility to protocols for physicians and individuals with rare and complex epilepsies across Europe for treatment will be further improved. There will be a further focus on training and education opportunities. We will also enhance the opportunities for building registries, and collaborative research for the benefit of individuals with rare and complex epilepsies across Europe.
Start date: 05/03/2019 - End date: 04/03/2022

Call: Multiannual Grant Agreements for European Reference Networks
Topic: 4.1 Support the establishment of a system of European reference networks for patients with conditions requiring highly specialised care and a particular concentration of resources o...
Topic: 4.1 Support the establishment of a system of European reference networks for patients with conditions requiring highly specialised care and a particular concentration of resources or expertise, as in the case of rare diseases, on the basis of criteria to be established under Directive 2011/24/EU.
3rd Health Programme (2014-2020)
SGA grant proposal year 3 to 5 for ERN RITA. [ern rita]
SGA proposal year 3 to 5 for ERN RITA.
The overall goal of the ERN RITA is to improve access to high-quality healthcare for patients. To ensure adequate and efficient use of the core service platforms...
SGA proposal year 3 to 5 for ERN RITA.
The overall goal of the ERN RITA is to improve access to high-quality healthcare for patients. To ensure adequate and efficient use of the core service platforms, i.e. the European Reference Networks Collaborative Platform (ECP) and the Clinical Patient Management System (CPMS), an established IT working group focuses on setting up these IT platforms. The developing IT tools are dedicated to e-learning, telemedicine and teleconsultation in order to guarantee the improvement in diagnosis and treatment of rare or low prevalence complex diseases across national borders of European Member States by sharing expertise in complex clinical cases. An Operational Helpdesk, set up by an additional grant and adjusted to the specific needs of ERN RITA, will work in close collaboration with the IT Working Party.
The informed consent form from the EC is in line with the European data protection standard to share health data within the ERNs to develop diagnoses and care plans. All HCPs need to check the provided consent form with their national or local authorities’ practices and combine the consent form with local standards if necessary. In most countries this is already done. The consent form and guidelines are available in the CPMS. These have been crafted with the GDPR in mind and has been considered a best-practice by the European Data Protection Supervisor (EDPS). It complies with the general data protection requirements in EU data protection law for consent.

Start date: 05/03/2019 - End date: 04/03/2022

Call: Multiannual Grant Agreements for European Reference Networks
Topic: 4.1 Support the establishment of a system of European reference networks for patients with conditions requiring highly specialised care and a particular concentration of resources o...
Topic: 4.1 Support the establishment of a system of European reference networks for patients with conditions requiring highly specialised care and a particular concentration of resources or expertise, as in the case of rare diseases, on the basis of criteria to be established under Directive 2011/24/EU.
3rd Health Programme (2014-2020)
EURO-NMD, an ERN for Rare Neuromuscular Diseases [EURO-NMD SGA]
EURO-NMD is a clinically oriented approach to the thematic grouping of neuromuscular disorders that builds on many years of networking experience in the NMD field. NMDs include a broad group of diseas...
EURO-NMD is a clinically oriented approach to the thematic grouping of neuromuscular disorders that builds on many years of networking experience in the NMD field. NMDs include a broad group of diseases with overall prevalence of 1/3500-1/2500 that represent a major cause of mortality and morbidity in children and adults. Their rarity and diversity pose specific challenges for healthcare provision and research. While individually rare, NMDs collectively affect an estimated 500,000 patients in Europe and result in life-long disabilities with significant costs for families and the healthcare system. Regional and national differences in care and incomplete implementation of standards lead to international disparities and divergent outcomes for NMD patients. NMD patients often lack timely and accurate diagnosis, and this impacts on survival and quality of life. Even patients with a condition diagnosable with existing gene tests typically wait 7 years for diagnosis – EURO-NMD aims to decrease time to diagnosis through implementation of diagnostic guidelines. A further 30% may remain without a confirmed genetic diagnosis after extensive testing. Through next-generation sequencing EURO-NMD aims to diagnose a further 15% of patients within the 5-year period. The ERN is a partner in the SOLVE-RD project that aims exactly at solving the unsolved cases and is also a partner in the EJP-RD. NMDs require a multidisciplinary team experienced in the specific clinical needs of the conditions comprising the ERN sub-groups: muscle, nerve, motor neuron, mitochondrial and neuromuscular junction diseases. During the last 2 years the working groups have collected and endorsed guidelines and standard operating procedures in collaboration with the learned societies. For the future the ERN aims to increase the teaching initiatives either through teaching courses, e-learning activities or supporting the networking of young professionals.
Start date: 01/03/2019 - End date: 28/02/2022

Call: Multiannual Grant Agreements for European Reference Networks
Topic: 4.1 Support the establishment of a system of European reference networks for patients with conditions requiring highly specialised care and a particular concentration of resources o...
Topic: 4.1 Support the establishment of a system of European reference networks for patients with conditions requiring highly specialised care and a particular concentration of resources or expertise, as in the case of rare diseases, on the basis of criteria to be established under Directive 2011/24/EU.